on Cheplapharm Arzneimittel GmbH (isin : DE000CHP2222)
CHEPLAPHARM Reports Stable Growth in the First Half of 2025
CHEPLAPHARM Arzneimittel GmbH, a key player in the pharmaceutical acquisition industry, reported a 12% increase in revenue to €813.4 million in the first half of 2025 compared to the latter part of 2024. EBITDA rose by 24% reaching €337.6 million, maintaining a strong margin of 42%.
After facing operational challenges in 2024, CHEPLAPHARM implemented a transformation program to stabilize its business. Co-CEO Sebastian Braun expressed satisfaction with the results, acknowledging improvements in process efficiency and operational stability.
The company successfully placed a €750 million bond, aiming to enhance financial flexibility and address medium-term maturities. CHEPLAPHARM continues to focus on acquiring established branded drugs, preparing for future market opportunities.
The workforce also expanded by 8%, reaching 789 employees. This growth occurs amid a competitive labor market, reinforcing CHEPLAPHARM's status as a leading employer.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Cheplapharm Arzneimittel GmbH news